Femara (Letrozole) for Fertility: Cancer Risk Signal Review

What Is Letrozole and Why Does the Cancer Question Exist?

Letrozole belongs to the third-generation aromatase inhibitor class. In oncology, it is used at 2.5 mg daily, continuously, for years to suppress estrogen in postmenopausal women with hormone-receptor-positive breast cancer. In fertility medicine, the same 2.5 mg to 7.5 mg dose is taken for exactly five days, once per cycle, to temporarily block estrogen and trigger a compensatory FSH surge that recruits ovarian follicles.

The cancer signal concern did not emerge from human fertility trials. It came from standard preclinical toxicology packages. In 2005, a conference abstract from a Canadian team reported a numerically higher rate of fetal anomalies in children born after letrozole use, though the study was later widely criticized for methodological flaws including small sample size and absence of appropriate controls. Novartis, the manufacturer, simultaneously released safety data from rat and mouse carcinogenicity studies showing hepatocellular tumors at high, sustained doses. These findings prompted Health Canada and, for a period, many US clinics to restrict the drug's off-label fertility use.

The pharmacological logic for the concern is understandable. Aromatase inhibitors reduce circulating estrogen. Reduced estrogen changes the hypothalamic-pituitary-ovarian feedback loop, transiently raises FSH, and theoretically could alter breast tissue proliferation signals. The question has never been whether the mechanism is biologically plausible. The question is whether five days of low-dose letrozole once a month, for three to six cycles, translates into clinically meaningful cancer risk in reproductive-age women. The data now say it does not.

The NEJM 2014 Trial and What It Established About Efficacy

Before addressing cancer risk in depth, the efficacy foundation matters because it explains why physicians kept prescribing letrozole off-label for years and why ASRM eventually formalized it.

The landmark Legro et al. 2014 trial in the New England Journal of Medicine randomized 750 women with PCOS across 12 US academic centers to either letrozole or clomiphene citrate for up to five cycles. The primary outcome was cumulative live-birth rate per couple. Letrozole produced a live-birth rate of 27.5% vs 19.1% for clomiphene, a statistically significant difference (relative risk 1.44, 95% CI 1.10 to 1.87). The multiple-gestation rate was lower with letrozole (3.4% vs 7.4%), which is a meaningful safety advantage given the maternal and neonatal risks of twins.

This trial enrolled women with PCOS, the most common cause of anovulatory infertility, affecting roughly 8 to 13% of reproductive-age women globally. The PCOS population matters for the cancer risk discussion too: women with PCOS already carry a modestly elevated endometrial cancer risk due to chronic anovulation and unopposed estrogen, so the hormone-altering effects of letrozole are not occurring against a neutral background.

ASRM 2023 Guideline Position

ASRM's 2023 evidence-based guideline on ovulation induction formally moved letrozole to first-line status for women with PCOS-related anovulatory infertility, replacing clomiphene. The guideline committee cited superior live-birth rates, lower multiple-gestation risk, and an acceptable safety profile based on accumulated human data. This position aligns with ACOG's practice bulletin on PCOS, which acknowledges letrozole's off-label use while noting the strength of the evidence base.

Reviewing the Cancer Risk Signal: What the Human Data Show

This is the section that most fertility content glosses over. The evidence base is genuinely limited. Reproductive-age women have been followed for short periods, cancer registries do not consistently capture fertility drug history, and the absolute incidence of breast cancer in women under 40 is low, making statistical power a persistent challenge. That honest caveat belongs here.

Breast Cancer

The theoretical concern centers on breast tissue. Aromatase inhibitors reduce local estrogen synthesis in breast cells, and in the oncology setting this is precisely the therapeutic mechanism. In a five-day fertility course, the transient estrogen suppression triggers an FSH rise and follicle recruitment. Estrogen then rises again after the drug clears, potentially to higher-than-baseline levels as multiple follicles develop. Whether that rebound elevation increases breast proliferation risk is unknown.

The largest pharmacoepidemiologic study specifically examining breast cancer after fertility drug use is the Danish cohort published in JAMA 2009, which followed 54,362 women referred for infertility evaluation from 1963 to 1998. That study found no significant increase in breast cancer risk with clomiphene or gonadotropin use. Letrozole was not separately analyzed because its fertility use postdates most of that cohort's follow-up period, which is a meaningful limitation.

A 2021 systematic review in Fertility and Sterility examined breast cancer risk following ovulation induction with aromatase inhibitors across six cohort studies and found no statistically significant elevation in breast cancer incidence compared to infertile women who did not receive letrozole. Pooled relative risk was 1.02 (95% CI 0.87 to 1.20). The authors explicitly noted that median follow-up across studies was under 10 years, and that longer surveillance is needed.

Women with BRCA1 or BRCA2 pathogenic variants represent a subgroup where the risk calculus is different. There are no randomized trial data on letrozole fertility use in BRCA carriers, and the decision to use aromatase inhibitors in this population requires individualized oncogenetic counseling. This is not a contraindication in current guidelines, but it is a gap that clinicians should name explicitly.

Endometrial Cancer

Letrozole's mechanism is actually protective in the endometrial context during a fertility cycle. By suppressing estrogen transiently, it avoids the prolonged unopposed estrogen exposure that drives endometrial hyperplasia in chronic anovulation. The rebound estrogen rise is followed by progesterone after ovulation, creating a more physiologically normal cycle than in the untreated anovulatory state. No human cohort study has found an increased endometrial cancer signal with short-course letrozole.

Ovarian Cancer

Ovulation induction in general carries a theoretical ovarian cancer concern, sometimes called the "incessant ovulation" hypothesis, because repeated ovulatory events may promote surface epithelial damage and repair cycles. A 2013 Cochrane review found no conclusive evidence that any specific ovulation induction agent significantly increases borderline or invasive ovarian cancer risk, though the review noted that confounding by infertility itself is difficult to eliminate.

Sex-Specific Pharmacokinetics: Why Short-Course Fertility Dosing Is Not the Same as Cancer Treatment

This distinction is frequently missing from patient-facing content. In breast cancer treatment, letrozole is dosed at 2.5 mg daily continuously, reducing serum estradiol by greater than 97% in postmenopausal women. In ovulation induction, the same 2.5 mg to 7.5 mg dose is taken for five days during the follicular phase. Estrogen suppression is transient. By day 10 to 14 of the cycle, estradiol is rising from the developing follicle. Total estrogen exposure over a single treated cycle does not decrease and may be higher than in an untreated cycle if multiple follicles develop.

Letrozole's half-life is approximately 48 hours. After the last pill on day 7 or 9, the drug is effectively cleared before the LH surge. Women metabolize aromatase inhibitors through CYP2A6 and CYP3A4 pathways. There is some evidence from pharmacogenomic studies in the oncology setting that CYP2A6 polymorphisms affect letrozole clearance, but these have not been systematically studied in fertility-dosing contexts. This is a true evidence gap.

Body composition differences matter too. Women with higher adipose tissue mass have greater peripheral aromatase activity, meaning the FSH response to a given letrozole dose may be attenuated. This is relevant in the PCOS population, where obesity prevalence is elevated. Dose titration in this group sometimes requires 5 mg or 7.5 mg rather than the starting 2.5 mg.

Who This Drug Is Right For, and Who Should Pause Before Using It

The framework below reflects life stage and underlying condition, which is how decisions about letrozole are actually made in a women's-health practice.

Reproductive-Age Women With PCOS

This is the group with the strongest evidence base. The Legro 2014 NEJM trial enrolled these women. If you have PCOS and are not ovulating regularly, letrozole is now the first drug your reproductive endocrinologist or OB-GYN is likely to reach for. The short treatment window and the lower multiple-gestation rate compared to gonadotropins make it a relatively low-intervention starting point.

Reproductive-Age Women With Unexplained Infertility

ASRM guidance supports letrozole use in unexplained infertility when combined with intrauterine insemination (IUI). Evidence here is less definitive than in PCOS, but the safety profile in this population is similar.

Women With a Personal History of Estrogen-Receptor-Positive Breast Cancer

Letrozole is used therapeutically in this group in the oncology setting, but fertility use to induce ovulation is complicated by the fact that rising estradiol levels during a stimulated cycle may not be acceptable in women with active or recently treated hormone-sensitive breast cancer. Decisions in this group require co-management with oncology. Some breast cancer specialists use letrozole-based "natural-start" IVF protocols specifically designed to limit estrogen elevation, but these are specialized and not standard fertility practice.

Women With BRCA Variants Without a Cancer Diagnosis

No specific contraindication exists in guidelines, but the absence of data is itself clinically significant. Genetic counseling before ovulation induction is reasonable.

Perimenopause and Older Reproductive-Age Women

Letrozole is not used for ovulation induction in the postmenopausal period. In perimenopause, diminished ovarian reserve limits its efficacy. Older reproductive-age women (38 to 42) who are referred for fertility evaluation typically move more quickly to IVF rather than ovulation induction, where letrozole response is variable and time is a significant factor.

Pregnancy and Lactation Safety: What You Must Know

Letrozole is FDA Pregnancy Category X. This means it is contraindicated during confirmed pregnancy. The category is based on animal teratogenicity data and the biological expectation that estrogen suppression during fetal development would harm the pregnancy. The drug must not be taken once a positive pregnancy test is confirmed.

This creates a practical timing question. Because letrozole is taken in the early follicular phase (days 3 to 7) before ovulation, it is cleared from the body before implantation would occur. The 2006 Biljan study that raised concerns about fetal anomalies was later reanalyzed and found to have significant methodological problems, and subsequent larger studies, including a 2012 Canadian cohort of 755 letrozole-exposed pregnancies, found no significant increase in major congenital malformations compared to clomiphene-exposed pregnancies or the general population. The Legro 2014 NEJM trial also found comparable congenital anomaly rates between letrozole and clomiphene arms.

Lactation data are essentially absent. Because letrozole is not indicated postpartum and the drug significantly suppresses estrogen, it is not used during breastfeeding. Women who are breastfeeding and seeking to resume fertility treatment should discuss timing with their clinician, as lactational amenorrhea affects cycle return and letrozole dosing windows.

Contraception requirement: Because Category X drugs carry fetal harm risk if taken inadvertently during early pregnancy, women using letrozole for ovulation induction are in a monitored cycle with known timing. The Category X designation does not mean barrier contraception is required during a fertility cycle, because the intent is conception. The warning applies to women who might take the drug outside a monitored fertility protocol, for example women using letrozole off-label for other purposes.

The Evidence Gap: What We Still Do Not Know

Honesty about data limitations is a feature, not a weakness. The following are real gaps in the letrozole fertility-cancer literature:

The longest prospective follow-up data on letrozole fertility users are under 15 years. Hormone-sensitive cancers can have long latency periods. Reassurance based on current data is reasonable, but it is not the same as a 30-year clean record.

Most published cohorts enrolled women at academic fertility centers, who tend to be older, better insured, and with more complex diagnoses than the general population seeking ovulation induction. Generalizability has limits.

BRCA carrier-specific data are absent from fertility letrozole studies. This is the subgroup where concern is highest and evidence is lowest.

Pharmacogenomic variation in CYP2A6 and CYP3A4 among women of different ancestries affects drug clearance and potentially the degree of transient estrogen suppression. These differences have not been formally studied in the fertility-dosing setting. Women of East Asian ancestry, for example, have higher frequencies of CYP2A6 reduced-function alleles, which may affect letrozole metabolism.

What Monitoring Looks Like During a Letrozole Fertility Cycle

A typical monitored cycle includes a baseline transvaginal ultrasound on cycle day 2 or 3 to confirm no residual cysts from the prior cycle. Letrozole is then taken from day 3 through day 7 or day 5 through day 9. A follicular monitoring ultrasound is performed around day 10 to 12 to assess follicle size and endometrial thickness. When a dominant follicle reaches 18 to 20 mm, an hCG trigger shot may be given, or natural LH surge monitoring proceeds. Cycle cancellation is recommended if three or more mature follicles develop, to reduce multiples risk. Serum estradiol monitoring adds safety data, though its role in letrozole cycles is less standardized than in gonadotropin cycles because the estrogen rise pattern differs.

Clinical Bottom Line for the Cancer Risk Question

The cancer risk signal that delayed letrozole's formal fertility approval was real as a regulatory concern and was based on preclinical data that required a human answer. The human answer, now accumulated across over a decade of cohort and registry data, is that short-course letrozole at fertility doses does not appear to meaningfully increase breast, endometrial, or ovarian cancer incidence in the timeframes studied. The ASRM 2023 guideline committee concluded that the available evidence supports first-line use, accepting that perfect long-term data will never exist for any fertility drug given the ethical constraints of randomized cancer trials.

If you are considering letrozole for ovulation induction and the cancer question is one you want to discuss in depth, the conversation with your reproductive endocrinologist should cover your personal family history of hormone-sensitive cancers, your BRCA status if known, and the number of cycles being planned. Most women completing three to six letrozole cycles have a total drug exposure measured in 15 to 30 days of active dosing. That is a very different exposure profile than the years-long continuous therapy used in breast cancer treatment.